RecruitingPhase 1NCT06889766
NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
Studying Melanoma of soft tissue
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Hospitalier Universitaire Vaudois
- Intervention
- NY-ESO-1 TCR redirected autologous T cell product(biological)
- Enrollment
- 9 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (2)
- Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Canton of Vaud, Switzerland
- Centre Hospitalier Universitaire Vaudois, Lausanne, Canton of Vaud, Switzerland
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06889766 on ClinicalTrials.govOther trials for Melanoma of soft tissue
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06942143An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid TumorsGuangzhou FineImmune Biotechnology Co., LTD.
- ACTIVE NOT RECRUITINGNANCT05121545Proton Pencil Beam Scanning GRID for Treatment of Bulky TumorsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGNCT05231655Ex VIvo DEtermiNed Cancer TherapySheffield Teaching Hospitals NHS Foundation Trust